Consequently, Group 3 tumors have the worst prognosis among the medulloblastoma subtypes, with five-year survival rates ranging from 50% to as low as 20–30% in cases of metastasis or MYC amplification [10]. This evidence concerns the gene MYC and medulloblastoma.